EUVIMEDEUVIMED entdecken
Open Access

Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6

Klara R Klein iD, Kim K B Clemmensen, Edwin Fong, Søren Olsen, Trine Abrahamsen, Ildiko Lingvay iD

Diabetes Care · 2024

DOI: 10.2337/dc23-1791 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, 2024. Verfasst von Klara R Klein und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, NC. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To assess the impact of concomitant metformin use on gastrointestinal adverse events during the initiation and titration of a glucagon-like peptide 1 receptor agonist (GLP-1RA). RESEARCH DESIGN AND METHODS Using data from four clinical trials of liraglutide and semaglutide (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results [LEADER], Semaglutide Treatment Effect in People with Obesity [STEP 2], Trial to Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in Subjects With Type 2 Diabetes [SUSTAIN-6], and Peptide Innovation for Early Diabetes Treatment [PIONEER] 6), we compared the incidence of gastrointestinal adverse events during GLP-1RA initiation and titration in participants with and without concomitant metformin use. RESULTS Of 16,996 participants, 12,928 (76%) were treated with metformin. Concomitant metformin use did not increase the percentage of participants who developed gastrointestinal adverse events or their severity during the observation window. Among participants experiencing gastrointestinal adverse events, metformin use did not increase study product discontinuation. Within treatment arms (GLP-1RA and placebo), a numerically higher percentage of metformin nonusers experienced gastrointestinal adverse events and discontinued the study product compared with metformin users. CONCLUSIONS Concomitant metformin use does not increase occurrence of gastrointestinal symptoms during GLP-1RA initiation or impact GLP-1RA discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2HumansHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsLiraglutideGlucagon-Like Peptides

Substanzen

MetforminHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsLiraglutideGlucagon-Like Peptides

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, NC.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • University of Texas Southwestern Medical Center, Dallas, TX.

ORCID-Profile: Klara R Klein, Ildiko Lingvay

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Klein, K. R., Clemmensen, K. K. B., Fong, E., Olsen, S., Abrahamsen, T., & Lingvay, I. (2024). Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6. Diabetes Care. https://doi.org/10.2337/dc23-1791

Vancouver

Klein KR, Clemmensen KKB, Fong E, Olsen S, Abrahamsen T, Lingvay I. Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6. Diabetes Care. 2024. doi:10.2337/dc23-1791

BibTeX
@article{Klein2024,
  author = {Klein, Klara R and Clemmensen, Kim K B and Fong, Edwin and Olsen, Søren and Abrahamsen, Trine and Lingvay, Ildiko},
  title = {Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6},
  journal = {Diabetes Care},
  year = {2024},
  doi = {10.2337/dc23-1791}
}
Kostenlos starten →